Hints and tips:
Related Special Reports
...The British Generic Manufacturers Association said on Monday that the voluntary scheme for branded medicines pricing and access (Vpas) would dent competition in the market for off-patent medicines delivered...
...US antitrust regulators also ordered Grail’s divestiture in April, a decision Illumina is appealing against....
...Last year, at the height of pricing negotiations, leaders from 16 of the world’s largest generic and biosimilar companies wrote asking for clarity on specific aspects of the deal....
...Some drugmakers have warned that prices for off-patent, generic medicines are now so low it has become unattractive to continue making them. Generics make up the majority of drugs used globally....
...“When this problem was finally resolved, pricing rules again.”...
...The pharmaceutical industry is close to agreeing a deal with the UK government over drug pricing, according to the chief financial officer of Swiss drugmaker Novartis....
...Another factor worth considering for ESG-minded investors in the health sector is the pricing of these drugs....
...BT said the claim related to a “technical” landline pricing issue that was “resolved by Ofcom in 2017”....
...Revenues are also expected to be hit by US pricing reforms. New treatments take time to come through....
...But it’s just a pricing mechanism! Could they leverage that into something with a big enough market share to make it sound anti-competitive?...
...That combination of correcting factors might include the growing number of Big Tech antitrust cases and the possibility that carbon pricing and copyright fines will challenge the “free” inputs necessary...
...Some are willing to prepare for long reviews as well as the possibility of litigation with the government in order to achieve their strategic goals.”...
...But the proposal has run into opposition from the pharmaceutical industry....
...Off-patent generic medicines make up the backbone of pharmaceutical care, but manufacturing issues, weak supply chains and low pricing have combined to create a “broken market” that makes these treatments...
...customers, competitors and antitrust experts....
...“These drug-pricing reforms are finally ending Big Pharma’s one-sided pricing power and giving patients a break.”...
...“She uses litigation, if necessary, as a platform to try and return, in her view, antitrust law to its original purpose of preventing industry consolidation or post-merger abuse,” he says....
...Access to long-acting drugs in poorer nations with high HIV rates remains patchy, despite the signing of licences for their generic manufacture....
...Almost 60 per cent of veterinary practices are now owned by large companies, up from 10 per cent in 2013, according to the UK’s antitrust watchdog, the Competition and Markets Authority....
...They also face the expiry of patents stretching to the end of the decade, which exposes $200bn of their top-selling branded drugs to generic competition and will squeeze revenues....
...The closure in April of a big US generics company Akorn Pharmaceuticals and Teva Pharmaceuticals’ decision last month to trim its generics portfolio highlight the extreme pressure the industry is under,...
...But despite the huge need for new drugs, many pharmaceutical companies have cut investment in antibiotics research....
...Private equity’s increasing ownership of veterinary clinics has put pressure on the pricing power of businesses like Dechra, while also attracting the attention of antitrust regulators in the US....
...The German paper echoes concerns raised by the pharmaceutical industry, which has argued that national pricing negotiations that are out of its control often hold back launches across the bloc....
International Edition